

DATES: Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before December 17, 2007 will be considered.

ADDRESSES: Requests for a copy of the patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to: Fatima Sayyid, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 435-4521; Facsimile: (301) 402-0220; e-mail: Fatima.Sayyid@nih.hhs.gov.

SUPPLEMENTARY INFORMATION: The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: October 11, 2007.

Steven M. Ferguson,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. E7-20520 Filed 10-16-07; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Treatment of Proliferative Disorders Using an Unexpected mTOR Kinase Inhibitor

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is contemplating the grant of an exclusive license to practice the invention embodied in PCT patent application

PCT/US2004/041265 filed December 9, 2004, entitled: "Methods for Suppressing an Immune Response or Treating a Proliferative Disorder" [HHS Reference Number: E-259-2003/0-PCT-02], to Emiliem, Inc., a Delaware Corporation, having a place of business in Emeryville, California. The field of use may be limited to the use of 2-(4-piperazinyl) substituted 4H-1-benzopyran-4-one compounds, including 2-(4-piperazinyl)-8-phenyl-4H-1-benzopyran-4-one (LY303511), for the treatment of cancer and/or other proliferative disorders not currently licensed, excluding the treatment and prevention of stenosis and restenosis. The United States of America is an assignee of the patent rights in these inventions.

DATES: Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before December 17, 2007 will be considered.

ADDRESSES: Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Susan Carson, D. Phil., Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Email: carsonsu@od.nih.gov; Telephone: (301) 435-5020; Facsimile: (301) 402-0220.

SUPPLEMENTARY INFORMATION: The search for specific kinase inhibitors is an active area of drug development as there is a continued need for effective anti-proliferative therapeutics with acceptable toxicities. The core invention is a novel method of use of one of the 4H-1-benzopyran-4-one derivatives (LY303511) which has been shown to target mTOR and casein kinase 2 (CK2) without affecting PI3K activity (JPET, May 26, 2005, doi: 10.1124/jpet.105.083550). Proof of concept data is available in an *in vivo* human xenograft PC-3 prostate tumor model, without observed toxicity. *In vitro* data suggest that 2-(4-piperazinyl)-8-phenyl-4H-1-benzopyran-4-one and derivatives may be effective in treating inflammatory, autoimmune and other proliferative disorders including restenosis, inflammatory bowel disease and a variety of cancers. Method of use claims are directed to derivatives of 2-(4-piperazinyl)-substituted 4H-1-benzopyran-4-one compounds as anti-proliferative, immunosuppressive, anti-inflammatory, anti-restenosis and anti-neoplastic agents.

The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: October 10, 2007.

Steven M. Ferguson,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. E7-20516 Filed 10-16-07; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HOMELAND SECURITY

Coast Guard

[Docket No. COTP Corpus Christi 07-085]

South Texas Area Maritime Security (STAMS) Committee; Vacancy

AGENCY: Coast Guard, DHS.

ACTION: Solicitation for membership.

SUMMARY: This notice requests individuals interested in serving on the South Texas Area Maritime Security (STAMS) Committee to submit their application for a potential opening on the committee to the Corpus Christi Captain of the Port/Federal Maritime Security Coordinator.

DATES: Applications should reach the Corpus Christi Captain of the Port/Federal Maritime Security Coordinator on or before October 30, 2007.

ADDRESSES: Requests for membership should be submitted to the Captain of the Port/Federal Maritime Security Coordinator at the following address:

Commander, USCG Sector Corpus Christi, 8930 Ocean Drive, Hangar 41, Corpus Christi, Texas 78419.

FOR FURTHER INFORMATION CONTACT: Mr. John Zarbock at 361-888-3162 (X501).

SUPPLEMENTARY INFORMATION:

Authority

Section 102 of the Maritime Transportation Security Act (MTSA) of 2002 (Pub. L. 107-295) added section 70112 to Title 46 of the U.S. Code, and authorized the Secretary of the

Department in which the Coast Guard is operating to establish Area Maritime Security Committees for any port area of the United States. (See 33 U.S.C. 1226; 46 U.S.C. 70112(a)(2); 33 CFR 1.05–1, 6.01; Department of Homeland Security Delegation No. 0170.1.) The MTTSA includes a provision exempting these Area Maritime Security (AMS) Committees from the Federal Advisory Committee Act (FACA), 5 U.S.C. App. (Pub. L. 92–436).

The South Texas Area Maritime Security (STAMS) Committee assists the Captain of the Port (COTP)/Federal Maritime Security Coordinator (FMSC) in the review and update of the STAMS Plan for the Corpus Christi Area of Responsibility. Such matters may include, but are not limited to: Identifying critical port infrastructure and operations; Identifying risks (threats, vulnerabilities, and consequences); Determining mitigation strategies and implementation methods; Developing and describing the process to continually evaluate overall port security by considering consequences and vulnerabilities, how they may change over time, and what additional mitigation strategies can be applied; and Providing advice to, and assisting the COTP/FMSC in, reviewing and updating the STAMS Plan.

STAMS Committee Membership

Applicants should have at least 5 years of experience related to maritime or port security operations. The STAMS Committee has ten members, made up of at least one individual from the Corpus Christi, Rio Grande Valley, Port of Port Lavaca-Point Comfort and Victoria Barge Canal, Port Security Working Groups (PSWG). The Coast Guard has one vacancy. We are seeking individuals interested in representing the Port of Port Lavaca-Point Comfort PSWG area with this solicitation. Applicants may be required to pass an appropriate security background check prior to appointment to the committee.

The member's term of office will be for 5 years; however, a member is eligible to serve an additional term of office. Members will not receive any salary or other compensation for their service on the STAMS Committee. In support of the Coast Guard's policy on gender and ethnic diversity, we encourage qualified women and members of minority groups to apply.

Request for Applications

Those seeking membership are not required to submit formal applications to the local COTP/FMSC. Nevertheless, because we do have an obligation to ensure that a specific number of

members have the prerequisite maritime security experience, we encourage the submission of resumes highlighting experience in the maritime and security industries.

Dated: September 4, 2007.

R.J. Paulison,

*Captain, U.S. Coast Guard, Corpus Christi
Captain of the Port/Federal Maritime Security
Coordinator.*

[FR Doc. E7–20497 Filed 10–16–07; 8:45 am]

BILLING CODE 4910–15–P

DEPARTMENT OF HOMELAND SECURITY

Coast Guard

[Docket No. USCG–2007–0003]

Temporary Relocation of the Coast Guard National Maritime Center (NMC)

AGENCY: Coast Guard, DHS.

ACTION: Notice.

SUMMARY: The Coast Guard National Maritime Center (NMC), which was located in Arlington, VA, has temporarily relocated to Kearneysville, WV, as part of a planned effort to restructure and centralize the Mariner Licensing and Documentation (MLD) Program. This notice provides information regarding both the NMC consolidation and the relocated NMC offices.

DATES: The temporary office in Kearneysville, WV, became operational on October 1, 2007. No further NMC operations are being carried out in Arlington, VA. In December 2007, the NMC will move to its permanent location in Martinsburg, WV.

ADDRESSES: The NMC's temporary address is: Commanding Officer, Coast Guard National Maritime Center, 130 East Burr Blvd., Kearneysville, WV 25430. In December, 2007, the NMC's permanent address will be: Commanding Officer, Coast Guard National Maritime Center, 100 Forbes Drive, Martinsburg, WV 25404.

FOR FURTHER INFORMATION CONTACT: If you have questions on this notice, call Mr. Jeffrey Brandt, National Maritime Center, telephone 304–724–9559.

SUPPLEMENTARY INFORMATION: The MLD Program restructuring and centralization plan, approved in 2005, will centralize many of the simultaneous efforts of 17 independently operating Regional Examination Centers (RECs) into one Merchant Mariner Credential (MMC) processing center in Martinsburg, WV. Having one MMC processing center will allow for more consistent procedures,

cost reduction, improved oversight, and improved mariner assistance.

The NMC has been reorganized into five divisions consisting of the Operations and Oversight Division (NMC–1), Mariner Training and Assessment Division (NMC–2), Program Support Division (NMC–3), Mariner Records Division (NMC–4), and Mariner Services Division (NMC–5).

We have temporarily relocated the NMC to Kearneysville, WV. On or about December 10, 2007, the NMC will relocate to its permanent address in Martinsburg, WV.

Dated: October 4, 2007.

Howard L. Hime,

*Acting Director of Commercial Regulations
and Standards, United States Coast Guard.*

[FR Doc. E7–20493 Filed 10–16–07; 8:45 am]

BILLING CODE 4910–15–P

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Construction of a Residential Community in Lake County, FL

AGENCY: Fish and Wildlife Service, Interior.

ACTION: Notice: Receipt of application for an incidental take permit; request for comments.

SUMMARY: We, the Fish and Wildlife Service (Service), announce the availability of an Incidental Take Permit (ITP) Application and Habitat Conservation Plan (HCP). Founders Ridge, LLC (applicant) requests an ITP for a duration of 10 years under the Endangered Species Act of 1973, as amended (Act). The applicant anticipates taking a total of approximately 32.18 acres of Florida scrub-jay (*Alphelocoma coerulescens*)—occupied habitat and approximately 1.85 acres of sand skink (*Neoseps reynoldsi*)—occupied habitat incidental to the construction of a residential development consisting of 963 units and associated amenities, in Lake County, Florida (project). The applicant's HCP describes the mitigation and minimization measures the applicant proposes to address the effects of the project to the Florida scrub-jay and sand skink.

DATES: We must receive any written comments on the ITP application and HCP on or before November 16, 2007.

ADDRESSES: If you wish to review the application and HCP, you may write the Field Supervisor at our Jacksonville Field Office, 6620 Southpoint Drive South, Suite 310, Jacksonville, FL